Please use this identifier to cite or link to this item:
|Title:||Pharmacokinetics of riluzole in beagle dogs|
|Author:||Perdigao, Ana P. L.|
Antunes, Natalicia de Jesus
Juni, Lucas T.
de Freitas, Noedi L.
Correa, Silvia V. M.
da Costa, Ronaldo C.
Moreno, Ronilson A.
Mendes, Gustavo D.
de Nucci, Gilberto
|Abstract:||Riluzole is a benzothiazole anticonvulsant used in the treatment of patients with amyotrophic lateral sclerosis and it is being investigated for clinical use in patients with spinal cord injury. The present study evaluated the pharmacokinetics of riluzole in beagle dogs after oral dose administration. Methods The oral doses (1.5, 5, 15 and 50 mg/kg) of riluzole were administered to beagle dogs and blood samples were collected from 0 h to 24 h post drug administration. Riluzole was quantified by liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). Results The method was sensitive, precise, accurate and selective to riluzole quantification in plasma of beagle dogs. The pharmacokinetics following oral administration was linear from 1.5 to 15 mg/kg and the t(1/2) was 2.16, 1.5, 1.8 and 3.0 h after oral administration of 1.5, 5.0, 15 and 50 mg/kg riluzole. Conclusion The riluzole pharmacokinetics was linear up to 15 mg/kg and had a significantlyshorter t(1/2) in beagle dogs than in humans|
|Editor:||Georg Thieme Verlag|
|Appears in Collections:||FCM - Artigos e Outros Documentos|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.